Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$104.39
+1.0%
$106.68
$72.21
$139.13
$5.09B0.48671,398 shs609,879 shs
CytoDyn Inc. stock logo
CYDY
CytoDyn
$0.27
+5.8%
$0.33
$0.10
$0.49
$322.27M1.291.33 million shs1.12 million shs
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
$25.59
$25.59
$9.90
$25.61
$2.21B0.191.29 million shs600 shs
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$68.49
$68.47
$21.65
$73.02
$4.62B0.452.07 million shs74 shs
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$0.81
+3.1%
$0.91
$0.61
$6.80
$44.34M1.25290,127 shs110,335 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
0.00%+2.65%-1.49%-11.38%+28.40%
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.00%-16.94%-24.29%+11.96%+85.25%
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00%0.00%0.00%0.00%0.00%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
0.00%-8.74%-12.70%+1.99%-79.39%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
4.6345 of 5 stars
4.51.00.04.51.44.20.6
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.0192 of 5 stars
0.01.00.00.00.80.00.0
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.2642 of 5 stars
0.00.00.04.00.00.00.6
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
3.3634 of 5 stars
3.54.00.00.02.03.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.06
Buy$172.3365.09% Upside
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.00
N/AN/AN/A
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
0.00
N/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00
N/AN/AN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
3.00
Buy$4.50455.97% Upside

Current Analyst Ratings Breakdown

Latest AXSM, CYDY, DCPH, PRLD, and GBT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/12/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$193.00 ➝ $186.00
6/10/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$180.00
6/9/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$153.00 ➝ $150.00
6/3/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$185.00
5/22/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$180.00 ➝ $180.00
5/14/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/7/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$200.00 ➝ $180.00
5/6/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$160.00 ➝ $165.00
5/6/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$160.00 ➝ $162.00
5/5/2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/29/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$190.00 ➝ $193.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$385.69M13.33N/AN/A$1.18 per share88.47
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/A($0.11) per shareN/A
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
$174.91M12.65N/AN/A$4.38 per share5.84
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$194.75M23.73N/AN/A$3.05 per share22.46
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$7M6.53N/AN/A$2.39 per share0.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$287.22M-$5.77N/A37.02N/A-64.39%-272.80%-36.69%8/4/2025 (Estimated)
CytoDyn Inc. stock logo
CYDY
CytoDyn
-$49.84M-$0.01N/AN/AN/AN/A-33.26%8/14/2025 (Estimated)
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
-$194.94M-$2.21N/AN/AN/A-108.86%-52.42%-40.05%N/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$127.17M-$1.69N/AN/AN/AN/A-89.18%-69.26%8/11/2025 (Estimated)

Latest AXSM, CYDY, DCPH, PRLD, and GBT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$0.47-$0.42+$0.05-$0.42N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/AN/A
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.48
2.03
1.96
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/A
0.30
0.30
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/A
4.19
3.94
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.92
6.88
6.17
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/A
5.18
5.18
CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38049.24 million38.21 millionOptionable
CytoDyn Inc. stock logo
CYDY
CytoDyn
201.25 billion1.24 billionNot Optionable
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
30086.48 million82.44 millionOptionable
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
45767.48 million64.17 millionOptionable
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
12056.46 million20.38 millionOptionable

Recent News About These Companies

Prelude Therapeutics Founder Acquires 28% More Stock
Prelude Therapeutics CEO buys $467K in common stock
Prelude Therapeutics stock surges on insider buying

New MarketBeat Followers Over Time

Media Sentiment Over Time

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$104.39 +1.03 (+1.00%)
As of 04:00 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

CytoDyn stock logo

CytoDyn OTCMKTS:CYDY

$0.27 +0.02 (+5.83%)
As of 03:59 PM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Deciphera Pharmaceuticals stock logo

Deciphera Pharmaceuticals NASDAQ:DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Global Blood Therapeutics stock logo

Global Blood Therapeutics NASDAQ:GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Prelude Therapeutics stock logo

Prelude Therapeutics NASDAQ:PRLD

$0.81 +0.02 (+3.07%)
As of 04:00 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.